Corporate Updates Round-Up: ESG Report, FDA Approvals, European Expansion, Innovative Technology, and Note Redemption
A summary of recent corporate announcements including environmental, social, and governance efforts, FDA approvals, European market expansion, innovative technology implementation, and financial updates.
Vancouver, BC: On June 27, 2024, First Mining Gold Corp. announced the publication of their third annual Environmental, Social and Governance (ESG) Report for 2023. This report details efforts in sustainable practices, ethical conduct, and transparent governance. Highlights include zero total recordable injury cases, 174 hours of health and safety training, 43% female full-time employees, and significant community investments.
Greenfield, IN: Elanco Animal Health announced updates regarding U.S. FDA approvals for Zenrelia and Credelio Quattro. Zenrelia is expected to receive final FDA approval in late Q3 2024 and launch in Q4 2024, with its first approval already received in Brazil. Credelio Quattro is expected to obtain FDA approval in Q4 2024 and launch in Q1 2025.
Atlanta, GA: Femasys Inc. will participate in the European Society of Human Reproduction and Embryology’s Annual Meeting in Amsterdam, following CE Mark approval for four of its products. The company aims to explore strategic partnerships in Europe.
Toronto, ON: dynaCERT Inc. announced a new purchase order of 84 HG1 HydraGEN
Units from Simply Green Distributors Inc., destined for a leading Canadian oil and gas drilling contractor. This technology is designed to enhance fuel economy and reduce emissions.
Bridgewater, NJ: Insmed Incorporated announced the redemption of all $225 million of its 1.75% Convertible Senior Notes due 2025. Scheduled for August 9, 2024, holders can convert their notes to shares of common stock prior to the redemption date.
